Literature DB >> 1977478

Cigarette smoking and neuroleptic-induced parkinsonism.

P Decina1, G Caracci, R Sandik, W Berman, S Mukherjee, P Scapicchio.   

Abstract

Several studies have reported an apparent protective effect of cigarette smoking for the risk of idiopathic Parkinson's disease (IPD). These observations are supported by neurochemical studies demonstrating enhancement of central dopaminergic neurotransmission by nicotine. We studied the prevalence and severity of neuroleptic-induced parkinsonism (NIP) in relation to cigarette smoking in a homogeneous sample of 130 psychiatric inpatients receiving long-term neuroleptic treatment. Despite the fact that smokers had significantly higher dosage of neuroleptics during the month prior to evaluation and longer exposure to medication, they presented with significantly less prevalence and severity of NIP than nonsmokers. These findings suggest that the inverse association between smoking and IPD may apply to NIP.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1977478     DOI: 10.1016/0006-3223(90)90483-i

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  14 in total

Review 1.  Co-morbidity of smoking in patients with psychiatric and substance use disorders.

Authors:  David Kalman; Sandra Baker Morissette; Tony P George
Journal:  Am J Addict       Date:  2005 Mar-Apr

Review 2.  Nicotinic mechanisms in the treatment of psychotic disorders: a focus on the α7 nicotinic receptor.

Authors:  Ann Olincy; Robert Freedman
Journal:  Handb Exp Pharmacol       Date:  2012

Review 3.  Movement disorders: neurodevelopment and neurobehavioural expression.

Authors:  T Archer; R J Beninger
Journal:  J Neural Transm (Vienna)       Date:  2006-10-06       Impact factor: 3.575

4.  Clinically significant psychotropic drug-drug interactions in the primary care setting.

Authors:  Brett A English; Marcus Dortch; Larry Ereshefsky; Stanford Jhee
Journal:  Curr Psychiatry Rep       Date:  2012-08       Impact factor: 5.285

5.  The effect of cigarette smoke exposure on spinal cord injury in rats.

Authors:  Zhong-kai Fan; Yang Cao; Gang Lv; Yan-song Wang; Zhan-peng Guo
Journal:  J Neurotrauma       Date:  2013-04-03       Impact factor: 5.269

Review 6.  Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.

Authors:  Ann Olincy; Karen E Stevens
Journal:  Biochem Pharmacol       Date:  2007-07-17       Impact factor: 5.858

7.  Cognitive performance and cigarette smoking in first-episode psychosis.

Authors:  Arantzazu Zabala; José Ignacio Eguiluz; Rafael Segarra; Sonsoles Enjuto; Jesús Ezcurra; Ana González Pinto; Miguel Gutiérrez
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-06-26       Impact factor: 5.270

Review 8.  Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia.

Authors:  Laura F Martin; William R Kem; Robert Freedman
Journal:  Psychopharmacology (Berl)       Date:  2004-02-19       Impact factor: 4.530

9.  Neuroadaptations to chronic exposure to drugs of abuse: relevance to depressive symptomatology seen across psychiatric diagnostic categories.

Authors:  Athina Markou; Paul J Kenny
Journal:  Neurotox Res       Date:  2002-06       Impact factor: 3.911

10.  Impact of an electronic cigarette on smoking reduction and cessation in schizophrenic smokers: a prospective 12-month pilot study.

Authors:  Pasquale Caponnetto; Roberta Auditore; Cristina Russo; Giorgio Carlo Cappello; Riccardo Polosa
Journal:  Int J Environ Res Public Health       Date:  2013-01-28       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.